Decoding Oncofusions: Unveiling Mechanisms, Clinical Impact, and Prospects for Personalized Cancer Therapies
Open Access
Abstract
Cancer-associated gene fusions, also known as oncofusions, have emerged as influential drivers of oncogenesis across a diverse range of cancer types. These genetic events occur via chromosomal translocations, deletions, and inversions, leading to the fusion of previously separate genes. Due to the drastic nature of these mutations, they often result in profound alterations of cellular behavior. The identification of oncofusions has revolutionized cancer research, with advancements in sequencing technologies facilitating the discovery of novel fusion events at an accelerated pace. Oncofusions exert their effects through the manipulation of critical cellular signaling pathways that regulate processes such as proliferation, differentiation, and survival. Extensive investigations have been conducted to understand the roles of oncofusions in solid tumors, leukemias, and lymphomas. Large-scale initiatives, including the Cancer Genome Atlas, have played a pivotal role in unraveling the landscape of oncofusions by characterizing a vast number of cancer samples across different tumor types. While validating the functional relevance of oncofusions remains a challenge, even non-driver mutations can hold significance in cancer treatment. Oncofusions have demonstrated potential value in the context of immunotherapy through the production of neoantigens. Their clinical importance has been observed in both treatment and diagnostic settings, with specific fusion events serving as therapeutic targets or diagnostic markers. However, despite the progress made, there is still considerable untapped potential within the field of oncofusions. Further research and validation efforts are necessary to understand their effects on a functional basis and to exploit the new targeted treatment avenues offered by oncofusions. Through further functional and clinical studies, oncofusions will enable the advancement of precision medicine and the drive towards more effective and specific treatments for cancer patients.Keywords
Funding Information
- Research Council of Finland
- Finnish Cancer Association
- Sigrid Juselius Foundation
This publication has 257 references indexed in Scilit:
- The Cancer Genome Atlas Pan-Cancer analysis projectNature Genetics, 2013
- Recurrent R-spondin fusions in colon cancerNature, 2012
- Age-Related Somatic Structural Changes in the Nuclear Genome of Human Blood CellsThe American Journal of Human Genetics, 2012
- Clonal evolution in cancerNature, 2012
- Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancerNature Medicine, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- An Integrated Network of Androgen Receptor, Polycomb, and TMPRSS2-ERG Gene Fusions in Prostate Cancer ProgressionCancer Cell, 2010
- Recurrent gene fusions in prostate cancerNature Reviews Cancer, 2008
- The oncogenic fusion protein Pax3–FKHR has a greater post-translational stability relative to Pax3 during early myogenesisBiochimica et Biophysica Acta (BBA) - General Subjects, 2007
- The impact of translocations and gene fusions on cancer causationNature Reviews Cancer, 2007